Somatostatin receptor 2A expression in von Hippel-Lindau-related hemangioblastomas.

Saya AhmadAngelika MuhlebnerTom J SnijdersWendy W de LengTatjana SeuteRachel S van Leeuwaarde

Published in: Cancer (2024)

SSTR2A is expressed in varying degrees in the majority of VHL-related hemangioblastomas. Future treatment with somatostatin analogues or even peptide receptor radionuclide treatment may be considered for SSTR2A-positive cases.

Keyphrases

poor prognosis
binding protein
combination therapy
molecular docking
neuroendocrine tumors
molecular dynamics simulations